Trial · NCT01338012
Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer
NCT01338012, Phase 2, Terminated, Dendreon; results first posted 2017-06-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer. Trials, record NCT01338012. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01338012
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer
- NCT number
- NCT01338012
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 8 participants, actual
- Lead sponsor
- Dendreon
- Conditions
- Prostate Cancer
- Interventions
- sipuleucel-T
- First posted
- 2011-04-19
- Last updated
- 2017-06-05
- Results first posted
- 2017-06-05
- Limitations and caveats
- This study was terminated early due to administrative reasons. Only 8 subjects were enrolled and treated. Given the small number of patients enrolled, analyses do not provide reliable results.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Study Participants Enrolled and Treated Prior to Study Termination | Study duration: date of first subject registration Dec 2011 and date of last subject visit April 2015 | Number of study participants that were enrolled and treated in this trial following completion of study P-11 and prior to study termination. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Study Participants Enrolled and Treated Prior to Study Termination | Study duration: date of first subject registration Dec 2011 and date of last subject visit April 2015 | This study was terminated early due to administrative reasons. Only eight subjects out of the ninety subjects planned were enrolled and treated. Given the small number of patients enrolled, results should be interpreted with caution. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Study Participants Enrolled and Treated Prior to Study Termination | Sipuleucel-T | 8 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Sipuleucel-T | 8 | |
| Overall Study | COMPLETED | Sipuleucel-T | 0 | |
| Overall Study | NOT COMPLETED | Sipuleucel-T | 8 |
Source ClinicalTrials.gov
Adverse events35
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Eye pain | Eye disorders | Sipuleucel-T | 1 | 8 | 1 |
| other | Nausea | Gastrointestinal disorders | Sipuleucel-T | 2 | 8 | 2 |
| other | Paraesthesia oral | Gastrointestinal disorders | Sipuleucel-T | 1 | 8 | 1 |
| other | Vomiting | Gastrointestinal disorders | Sipuleucel-T | 1 | 8 | 2 |
| other | Chills | General disorders | Sipuleucel-T | 5 | 8 | 6 |
| other | Fatigue | General disorders | Sipuleucel-T | 4 | 8 | 9 |
| other | Pyrexia | General disorders | Sipuleucel-T | 2 | 8 | 2 |
| other | Asthenia | General disorders | Sipuleucel-T | 1 | 8 | 1 |
| other | Malaise | General disorders | Sipuleucel-T | 1 | 8 | 1 |
| other | Pain | General disorders | Sipuleucel-T | 1 | 8 | 3 |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Sipuleucel-T | 4 | 8 |
| Total, other adverse events | Sipuleucel-T | 8 | 8 |
| Total, serious adverse events | Sipuleucel-T | 2 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01338012
GET https://conductscience.org/api/trials/v1/NCT01338012/events?page=2